An Open-Label Phase 2 Study to Evaluate the Safety, Tolerability, and Effect on Albuminuria of MZE829 in Adults With Proteinuric Chronic Kidney Disease and the APOL1 High Risk Genotype
Maze Therapeutics
Summary
This is purpose of this study is to evaluate the safety, tolerability, and effect on Albuminuria of MZE829 in Adults with APOL1 Kidney Disease
Description
An open-label Phase 2 study is designed to evaluate the safety, tolerability, and effect on Albuminuria of MZE829 in Adults with Proteinuric Chronic Kidney Disease and the APOL1 High Risk Genotype.
Eligibility
- Age range
- 18–68 years
- Sex
- All
- Healthy volunteers
- No
Key Inclusion Criteria: * APOL1 high risk genotype of G1/G1, G2/G2, or G1/G2 * Chronic kidney disease with persistent albuminuria Key Exclusion Criteria: * Organ or bone marrow transplantation * History of cancer within past 2 years, excepted for treated non-melanoma skin cancer, stage 0 cervical cancer, or stage 1 prostate cancer * Conditions that may alter drug absorption, e.g., history of bariatric surgery * Type I diabetes * Pregnant or currently nursing Other inclusion/exclusion criteria defined in protocol apply.
Interventions
- DrugMZE829
Capsules for oral administration
Locations (81)
- Research SiteDecatur, Alabama
- Research SiteHuntsville, Alabama
- Research SiteMontgomery, Alabama
- Research SiteMontgomery, Alabama
- Research SiteGranada Hills, California
- Research SiteBloomfield, Connecticut